drugset / Trial / NCT02592018
Immunologic Response to Secukinumab in Plaque Psoriasis
Phase 4
Completed
15 enrolled
University of California, San Francisco
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelBasic science
Summary
This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.
Timeline
- Start
- 2016-10
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |